Literature DB >> 1622851

Adriamycin in hyperthermic perfusion for advanced limb sarcomas.

C R Rossi1, A Vecchiato, P P Da Pian, D Nitti, M Lise, P L Melanotte, S Turra, F Vigliani.   

Abstract

From February 1989 to April 1991, 12 hyperthermic limb perfusions (HLP) with adriamycin (ADR) were performed in 12 patients with high grade soft tissue sarcomas (9 in the leg and 3 in the arm); two were at A.J.C. stage IIb, eight stage IIIb and two stage IV. ADR (0.7-1.5 mg/kg) was administered in bolus at a mean temperature of 41.5 degrees C and perfused for 60 min. No systemic toxicity was reported; seven patients had grade II locoregional toxicity, another four grade III and one grade IV. Tumor necrosis (radiological evaluation) was less than 25% in two patients, 25% to 50% in two, 50% to 75% in five and greater than 75% in three. Limb sparing surgery was feasible in ten patients. At present eight patients are alive; three had local recurrence and four distant metastases.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1622851     DOI: 10.1093/annonc/3.suppl_2.s111

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  2 in total

1.  TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects.

Authors:  A H van der Veen; J H de Wilt; A M Eggermont; S T van Tiel; A L Seynhaeve; T L ten Hagen
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

2.  Lack of efficacy of Doxil in TNF-alpha-based isolated limb perfusion in sarcoma-bearing rats.

Authors:  T L M ten Hagen; S Hoving; G Ambagtsheer; S T van Tiel; A M M Eggermont
Journal:  Br J Cancer       Date:  2004-05-04       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.